Bone Biologics Corp [NASDAQ: BBLG] closed the trading session at $2.85 on 2025-09-04. The day’s price range saw the stock hit a low of $2.5101, while the highest price level was $4.1299.
The stocks have a year to date performance of -66.07 percent and weekly performance of 32.56 percent. The stock has been moved at -45.40 percent over the last six months. The stock has performed 5.95 percent around the most recent 30 days and changed -42.63 percent over the most recent 3-months.
If compared to the average trading volume of 503.41K shares, BBLG reached to a volume of 120810910 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Bone Biologics Corp [BBLG]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBLG shares is $22.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBLG stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 0.73, with the Price to Cash per share for the same quarter was set at 3.69.
BBLG stock trade performance evaluation
Bone Biologics Corp [BBLG] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.56. With this latest performance, BBLG shares gained by 5.95% in over the last four-week period, additionally sinking by -45.40% over the last 6 months – not to mention a drop of -49.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBLG stock in for the last two-week period is set at 62.84, with the RSI for the last a single of trading hit 0.32, and the three-weeks RSI is set at 0.28 for Bone Biologics Corp [BBLG]. The present Moving Average for the last 50 days of trading for this stock 2.79, while it was recorded at 2.27 for the last single week of trading, and 4.89 for the last 200 days.
Bone Biologics Corp (BBLG) Capital Structure & Debt Analysis
According to recent financial data for Bone Biologics Corp. ( BBLG), the Return on Equity (ROE) stands at -88.80%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -82.79%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Bone Biologics Corp’s Return on Invested Capital (ROIC) is -112.69%, showcasing its effectiveness in deploying capital for earnings.
Bone Biologics Corp (BBLG) Efficiency & Liquidity Metrics
Based on Bone Biologics Corp’s (BBLG) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Bone Biologics Corp (BBLG) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Bone Biologics Corp. (BBLG) effectively leverages its workforce, generating an average of -$3715000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 17.24% and a Quick Ratio of 17.24%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Bone Biologics Corp [BBLG] stock
With the latest financial reports released by the company, Bone Biologics Corp posted -1.33/share EPS, while the average EPS was predicted by analysts to be reported at -0.58/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.75. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BBLG. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bone Biologics Corp go to 79.61%.
Bone Biologics Corp [BBLG]: Institutional Ownership
There are presently around $0.12%, or 0.13%% of BBLG stock, in the hands of institutional investors. The top three institutional holders of BBLG stocks are: UBS GROUP AG with ownership of 33707.0 shares, which is approximately 5.1%. HRT FINANCIAL LP, holding 17519.0 shares of the stock with an approximate value of $$21000.0 in BBLG stocks shares; and HRT FINANCIAL LP, currently with $$7063.0 in BBLG stock with ownership which is approximately 0.8759%.
